Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Tax

Legal developments in transfer pricing rules in Kazakhstan in the pharmaceuticals sector

Aigerim Serikbayeva · November 2026 · 10 min read

Kazakhstan tightened transfer pricing rules for pharmaceutical companies in 2025–26. Key changes for foreign pharma investors. Make an enquiry.

Amendments to Kazakhstan's transfer pricing framework that took effect in the period from 2025 to 2026 have materially altered the compliance burden for foreign pharmaceutical companies operating in, or supplying into, the country. The changes tighten documentation requirements, expand the categories of controlled transactions subject to arm's-length scrutiny, and introduce sector-specific audit indicators that target pharmaceutical supply chains directly. For in-house counsel at foreign pharma groups with Kazakhstan operations, or for corporate advisers managing cross-border Kazakhstan–Russia pricing arrangements within EAEU structures, the practical implications are immediate and, in some cases, retroactive in their effect on open audit periods.

§ I. What has changed – the 2025–2026 transfer pricing amendments

Kazakhstan's approach to transfer pricing has followed an OECD-influenced trajectory since the early 2010s, with successive iterations of the Tax Code progressively incorporating the arm's-length principle, documentation requirements, and comparables analysis into domestic law. The amendments that became operative in 2025 and early 2026 represent the most significant recalibration of that framework in the past decade.

Before the amendments, the Kazakhstan transfer pricing rules applied principally to transactions between related parties and to transactions with counterparties registered in low-tax or preferential jurisdictions. The documentation threshold – the transaction value above which a taxpayer was required to prepare and maintain a full TP file – was set at a level that many mid-sized intra-group transactions in the pharmaceutical sector could, in practice, avoid through careful structuring. Price benchmarking methodologies were codified but the State Revenue Committee's audit guidance on sector-specific comparables remained relatively undeveloped for pharmaceuticals.

After the amendments, several things changed in a manner directly relevant to pharmaceutical companies. First, the documentation threshold was revised downward, bringing a greater proportion of intra-group pharmaceutical transactions – including supplies of active pharmaceutical ingredients, formulated medicines, and drug registration licences – within the mandatory documentation regime. Second, the amendments introduced a framework for country-by-country reporting aligned with OECD BEPS Action 13, with an obligation that applies to the Kazakhstan constituent entities of multinational enterprise groups above a consolidated revenue threshold. Third, the State Revenue Committee published updated audit guidance that lists pharmaceutical product transfers and intra-group royalties for marketing authorisations as priority risk categories. Fourth, the interaction between customs valuation and TP pricing – a long-standing source of practical uncertainty in Kazakhstan – was addressed, though not fully resolved, through new administrative guidance on simultaneous audit coordination.

"The 2025–2026 cycle of amendments closes procedural gaps that large pharmaceutical groups had previously navigated through documentation minimisation strategies. The combination of a lower threshold, CbCR obligations, and sector audit indicators means that the compliance question is no longer whether TP documentation is required, but whether what exists is defensible." — Aigerim Serikbayeva, Contributing Regional Analyst — Kazakhstan, Vetrov & Partners

The before/after framing is not merely procedural. The effective lowering of the threshold combined with retroactive application to open tax periods – typically the three calendar years preceding an audit notice – means that pharmaceutical companies that did not prepare contemporaneous TP documentation for 2023 or 2024 intra-group transactions may face documentation penalties even if their pricing was, substantively, at arm's length.

§ II. Which pharmaceutical companies are most affected by the Kazakhstan transfer pricing changes?

The impact is not uniform across the pharmaceutical sector, and the risk profile differs substantially depending on the structure of a company's Kazakhstan operations, the nature of its intra-group transactions, and the jurisdictions through which it channels its regional supply chain.

Foreign pharmaceutical groups with a Kazakhstan legal entity – whether a subsidiary, representative office with an assessed permanent establishment, or a licensed distributor under a related-party arrangement – fall squarely within the scope of the revised rules. The critical distinction is between groups that operate through a locally incorporated entity and those that supply Kazakhstan exclusively through third-party distributors. For the latter, TP exposure in Kazakhstan is typically limited to the distributor selection and pricing arrangement itself; for the former, every intra-group transaction touching the Kazakhstan entity is a potential audit trigger.

The transaction categories that the State Revenue Committee audit guidance identifies as highest priority for pharmaceutical companies include: intra-group supply of formulated medicines from a manufacturing affiliate to the Kazakhstan distributor or marketing entity; transfers of active pharmaceutical ingredients across the EAEU and CIS supply chain, including on the Russia–Kazakhstan corridor which represents a significant volume route for generic manufacturers; intercompany service charges and management fees from regional headquarters to the Kazakhstan entity; and royalties or licence fees paid to an IP-holding entity – whether within or outside the EAEU – for the right to use drug registrations, marketing authorisations, or trade marks in the Kazakhstan market.

Cross-border Kazakhstan–Russia pharmaceutical transactions deserve specific attention. The EAEU customs union harmonises the formal customs valuation rules applied to goods moving between member states, but TP rules in Kazakhstan and Russia operate under separate domestic frameworks. A pharmaceutical group that has agreed an intra-group transfer price for goods moving from a Russian manufacturing entity to a Kazakhstan affiliate for onward distribution faces the practical difficulty of demonstrating that the same price satisfies the arm's-length standard under both the Kazakhstan Tax Code and the corresponding Russian TP rules – which have their own comparables requirements. Where these analyses diverge, the group faces the risk of simultaneous TP adjustments in both jurisdictions without a mutual agreement procedure readily available for EAEU-internal transactions.

Originator pharmaceutical companies supplying branded medicines through a Kazakhstan entity face a distinct but equally pressing concern: the updated audit guidance specifically flags intercompany royalties for marketing authorisations as a priority risk area. Marketing authorisation licences in Kazakhstan are subject to local registration requirements, and the fee paid by the Kazakhstan entity to the global IP-holding company for access to the authorisation – and any associated know-how or clinical data package – is now subject to rigorous benchmarking scrutiny. The comparable uncontrolled price method, which is the approach most frequently applied by the State Revenue Committee in assessments, is particularly difficult to apply to unique pharmaceutical IP, creating a practical tension between the preferred audit methodology and the economic reality of the transaction.

§ III. What foreign pharmaceutical companies should do now

The combination of a revised threshold, new documentation requirements, sector-targeted audit guidance, and the retroactive character of open-period exposure means that foreign pharmaceutical companies cannot treat these amendments as a forward-looking compliance project only. A retrospective review of intra-group pricing for the three preceding tax years is a necessary first step.

The practical priorities, in order, are as follows. First, map the controlled transactions: identify every intra-group transaction touching the Kazakhstan entity for the current and preceding three tax periods and assess whether each falls within the revised documentation threshold. This mapping should include not only goods transactions but also service charges, IP licences, and financing arrangements. Transactions on the Russia–Kazakhstan corridor, and any other EAEU-internal supply routes, should be flagged separately given the dual-jurisdiction TP risk.

Second, assess documentation adequacy: for any transaction within scope, determine whether contemporaneous documentation – local file, and master file if the group's consolidated revenue meets the CbCR threshold – was prepared at the time of the transaction. Documentation prepared retrospectively is not prohibited under the Kazakhstan rules, but it carries significantly less evidential weight in an audit and does not shield against documentation penalties if an audit notice is received before the file is completed.

Third, benchmark pricing: the State Revenue Committee's audit guidance on pharmaceutical transactions indicates a preference for the comparable uncontrolled price method for tangible goods and a transactional net margin method for service charges and distributions. For royalties and marketing authorisation licences – where CUP data is thin – the residual profit split method or a detailed cost-based analysis will typically be necessary. Foreign pharmaceutical companies that have applied a methodology in a different jurisdiction should not assume that methodology will satisfy the Kazakhstan comparables requirements without a jurisdiction-specific analysis.

Fourth, coordinate with Russian TP counsel on EAEU corridor transactions: for pharmaceutical groups with an active Russia–Kazakhstan intra-group supply arrangement, a coordinated TP analysis that tests the agreed price against both the Kazakhstan and Russian arm's-length standards simultaneously is materially more defensible – and considerably cheaper to prepare – than two separate analyses conducted after an audit notice has been received in one jurisdiction.

§ IV. Open questions and pending developments

Not all aspects of the 2025–2026 amendments have been fully resolved at the level of implementing regulations or published audit guidance, and foreign pharmaceutical companies should be aware of three areas of continuing uncertainty.

The interaction between Kazakhstan's revised TP rules and the EAEU-level harmonisation agenda remains incomplete. EAEU working groups have discussed the development of a common transfer pricing methodology framework for intra-union transactions, but as of the publication of this article no binding EAEU-level TP instrument has been adopted. Until such an instrument exists, pharmaceutical groups operating across multiple EAEU member states must navigate separate domestic frameworks in each jurisdiction. The divergence between Kazakhstan and Russian comparables methodologies for pharmaceutical transactions is the most commercially significant gap in the current landscape.

The scope of the country-by-country reporting obligation – specifically, the consolidated revenue threshold above which Kazakhstan constituent entities must participate in the CbCR framework – has been the subject of interpretive guidance that is not yet fully aligned with the administrative practice of the State Revenue Committee. Foreign pharmaceutical groups that sit at or near the threshold in a given year should seek a specific assessment of whether their Kazakhstan entity triggers a local CbCR filing obligation, rather than relying on a group-level determination made by the ultimate parent's tax function in a different jurisdiction.

The status of advance pricing agreements in Kazakhstan – which are available in principle under the Tax Code but have historically been difficult to obtain in practice for pharmaceutical transactions – may improve under the revised procedural framework. The amendments include provisions intended to streamline the APA application process, though the extent to which this will translate into a practically accessible regime for foreign pharmaceutical companies will only become clear as the State Revenue Committee's administrative practice develops. Companies with long-term intra-group supply arrangements and significant Kazakhstan volumes may wish to initiate an APA application in anticipation of that development.

Frequently asked questions

Q: What specifically changed in Kazakhstan's transfer pricing rules for the pharmaceuticals sector in 2025–2026?

A: The principal changes were: a reduction in the documentation threshold, bringing a wider range of intra-group pharmaceutical transactions within the mandatory TP file requirement; introduction of a country-by-country reporting obligation aligned with OECD BEPS Action 13; and updated State Revenue Committee audit guidance that designates pharmaceutical product supplies, marketing authorisation royalties, and management service charges as priority risk categories. The amendments also addressed, though did not fully resolve, the interaction between customs valuation and TP pricing for goods transactions. Documentation prepared before an audit notice is received carries significantly greater evidential weight than retrospective analysis.

Q: Which foreign pharmaceutical companies operating in Kazakhstan are most at risk under the revised rules?

A: Companies operating through a locally incorporated Kazakhstan entity with intra-group transactions – particularly those involving goods transfers from a Russian or other EAEU affiliate, royalties for drug marketing authorisations, or management service charges from a regional headquarters – face the highest immediate exposure. The retroactive effect on open audit periods (typically three calendar years) means that companies that did not prepare contemporaneous TP documentation for 2023 and 2024 transactions may face documentation penalties even where the underlying pricing was defensible on the merits. Companies with active Russia–Kazakhstan intra-group supply chains face an additional risk of simultaneous TP adjustments in both jurisdictions.

Q: What should foreign pharmaceutical companies do to address the Kazakhstan transfer pricing changes?

A: The immediate priorities are: map all controlled transactions touching the Kazakhstan entity for the current and preceding three tax years; assess whether contemporaneous documentation exists for each in-scope transaction; benchmark pricing against the State Revenue Committee's preferred methodologies (CUP for goods, TNMM for services and distributions, residual profit split or cost-based analysis for pharmaceutical IP royalties); and, for Russia–Kazakhstan corridor transactions, coordinate the Kazakhstan TP analysis with Russian counsel to avoid simultaneous inconsistent adjustments. Companies near the CbCR consolidated revenue threshold should also seek a specific assessment of their Kazakhstan local filing obligations.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry